| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC | Executive VP, Research & Dev | Restricted Stock Units | 50,655 | $1,517,624 | $29.96 | 10 Feb 2023 | Direct |
| AVADEL PHARMACEUTICALS PLC | Chief Medical Officer | Stock Option (Right to Buy) | 275,000 | 14 Feb 2022 | Direct | ||
| ACADIA PHARMACEUTICALS INC | Executive VP, Research & Dev | Non-Qualified Stock Option (Right to Buy) | 237,296 | 10 Feb 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | 10 Feb 2023 | 2 | $0 | 4 | Executive VP, Research & Dev | 13 Feb 2023, 17:45 |
| ACAD | ACADIA PHARMACEUTICALS INC | 01 Feb 2023 | 0 | $0 | 3 | Executive VP, Research & Dev | 13 Feb 2023, 17:40 |
| AVDL | AVADEL PHARMACEUTICALS PLC | 14 Feb 2022 | 1 | $0 | 4 | Chief Medical Officer | 16 Feb 2022, 15:40 |
| AVDL | AVADEL PHARMACEUTICALS PLC | 14 Feb 2022 | 0 | $0 | 3 | Chief Medical Officer | 16 Feb 2022, 15:25 |